CEO Punit Dhillon highlighted significant progress with the clinical development of nimacimab, including the completion of patient enrollment for the CBeyond Phase IIa trial ahead of schedule.

Enlivex Therapeutics Ltd. has announced the completion of patient enrollment in the Phase II stage of its clinical trial for Allocetra™, an immunotherapy for moderate to severe knee ...

Merit Medical Systems, Inc. MMSI, on Monday, announced the enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ...